Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.975
-0.085 (-8.00%)
At close: Nov 15, 2024, 4:00 PM
0.980
+0.005 (0.49%)
After-hours: Nov 15, 2024, 7:16 PM EST
Lexicon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 5.23 | 1.2 | 0.14 | 0.3 | 24 | 322.07 | Upgrade
|
| Revenue Growth (YoY) | 886.60% | 766.19% | -53.36% | -98.76% | -92.55% | 409.54% | Upgrade
|
| Cost of Revenue | 72.9 | 58.97 | 52.82 | 55.05 | 153.05 | 95.16 | Upgrade
|
| Gross Profit | -67.67 | -57.77 | -52.68 | -54.75 | -129.06 | 226.92 | Upgrade
|
| Selling, General & Admin | 143.45 | 113.98 | 48.08 | 32.34 | 44.23 | 56.84 | Upgrade
|
| Operating Expenses | 143.45 | 113.98 | 48.08 | 32.34 | 44.23 | 56.84 | Upgrade
|
| Operating Income | -211.12 | -171.75 | -100.76 | -87.09 | -173.29 | 170.08 | Upgrade
|
| Interest Expense | -17.14 | -13.1 | -2.78 | -0.8 | -14.54 | -20.68 | Upgrade
|
| Interest & Investment Income | 11.87 | 7.73 | 1.6 | 0.13 | 2.77 | 3.35 | Upgrade
|
| EBT Excluding Unusual Items | -216.39 | -177.12 | -101.94 | -87.76 | -185.06 | 152.76 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -5.5 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 132.59 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -1.6 | -28.64 | Upgrade
|
| Other Unusual Items | - | - | - | - | 1 | - | Upgrade
|
| Pretax Income | -216.39 | -177.12 | -101.94 | -87.76 | -58.57 | 124.12 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -6.01 | Upgrade
|
| Net Income | -216.39 | -177.12 | -101.94 | -87.76 | -58.57 | 130.13 | Upgrade
|
| Net Income to Common | -216.39 | -177.12 | -101.94 | -87.76 | -58.57 | 130.13 | Upgrade
|
| Shares Outstanding (Basic) | 291 | 221 | 166 | 146 | 111 | 106 | Upgrade
|
| Shares Outstanding (Diluted) | 291 | 221 | 166 | 146 | 111 | 117 | Upgrade
|
| Shares Change (YoY) | 40.47% | 33.43% | 13.79% | 31.41% | -5.06% | 10.32% | Upgrade
|
| EPS (Basic) | -0.74 | -0.80 | -0.62 | -0.60 | -0.53 | 1.23 | Upgrade
|
| EPS (Diluted) | -0.74 | -0.80 | -0.62 | -0.60 | -0.53 | 1.16 | Upgrade
|
| Free Cash Flow | -208.39 | -162.37 | -90.18 | -88.24 | -143.06 | 113.74 | Upgrade
|
| Free Cash Flow Per Share | -0.72 | -0.73 | -0.54 | -0.61 | -1.29 | 0.97 | Upgrade
|
| Gross Margin | - | - | - | - | - | 70.46% | Upgrade
|
| Operating Margin | -4037.43% | -14264.95% | -72489.21% | -29224.83% | -722.17% | 52.81% | Upgrade
|
| Profit Margin | -4138.32% | -14710.88% | -73341.01% | -29448.99% | -244.11% | 40.40% | Upgrade
|
| Free Cash Flow Margin | -3985.35% | -13485.63% | -64875.54% | -29610.07% | -596.19% | 35.31% | Upgrade
|
| EBITDA | -210.56 | -171.2 | -100.33 | -86.8 | -170.35 | 173.74 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | 53.94% | Upgrade
|
| D&A For EBITDA | 0.56 | 0.55 | 0.43 | 0.29 | 2.93 | 3.65 | Upgrade
|
| EBIT | -211.12 | -171.75 | -100.76 | -87.09 | -173.29 | 170.08 | Upgrade
|
| EBIT Margin | - | - | - | - | - | 52.81% | Upgrade
|
| Revenue as Reported | 5.23 | 1.2 | 0.14 | 0.3 | 24 | 322.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.